Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The amendment provides an additional $14 million in available funding, increasing the total potential value of the contract to $214 million.“Our BARDA partnership helps fund the development of the INTERCEPT Blood System for red blood cells (RBC) and is integral to our mission to secure blood safety and availability in the face of pandemic threats,” said Dr. Nina Mufti, Cerus’ vice president, development and RBC program leader. “The INTERCEPT technology for RBCs is an important extension of our current product portfolio for platelets and plasma because it addresses the most frequently transfused component.”The $14 million contract amendment includes additional funding for RedeS, the Company’s ongoing Phase 3 U.S. clinical study evaluating the safety and efficacy of INTERCEPT RBCs in patients
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus (NASDAQ:CERS) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides OutlookBusiness Wire
- TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS) [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America [Yahoo! Finance]Yahoo! Finance
CERS
Earnings
- 11/6/25 - Beat
CERS
Sec Filings
- 1/12/26 - Form 8-K
- 11/26/25 - Form 4
- 11/24/25 - Form 144
- CERS's page on the SEC website